1. Home
  2. SUNS vs SCYX Comparison

SUNS vs SCYX Comparison

Compare SUNS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrise Realty Trust Inc.

SUNS

Sunrise Realty Trust Inc.

HOLD

Current Price

$10.26

Market Cap

128.7M

Sector

Real Estate

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.64

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUNS
SCYX
Founded
2023
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.7M
26.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SUNS
SCYX
Price
$10.26
$0.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$13.50
$3.00
AVG Volume (30 Days)
89.8K
469.7K
Earning Date
11-13-2025
11-05-2025
Dividend Yield
11.65%
N/A
EPS Growth
1112.46
N/A
EPS
1.09
N/A
Revenue
$19,384,703.00
$2,932,000.00
Revenue This Year
$174.58
$167.73
Revenue Next Year
$60.45
$290.78
P/E Ratio
$9.44
N/A
Revenue Growth
2540.16
N/A
52 Week Low
$7.80
$0.57
52 Week High
$14.87
$1.49

Technical Indicators

Market Signals
Indicator
SUNS
SCYX
Relative Strength Index (RSI) 57.05 43.25
Support Level $10.06 $0.63
Resistance Level $10.45 $0.67
Average True Range (ATR) 0.32 0.03
MACD 0.04 0.00
Stochastic Oscillator 78.24 23.68

Price Performance

Historical Comparison
SUNS
SCYX

About SUNS Sunrise Realty Trust Inc.

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: